• FY26 Underlying NPAT expected to be $17M to $18M
• Lower Australian ART market activity
• Increased national market share to 20.1%
• Growth in international operations
• Operational and cost efficiency initiatives underway

Monash IVF Group Limited (ASX: MVF) has updated its FY26 earnings outlook, anticipating Underlying NPAT to be between $17 million and $18 million, driven by lower-than-expected Australian ART market activity. The company reports a 4.7% decline in stimulated cycle volumes in Australia as of April, continuing into May and June. Despite market challenges, Monash IVF has increased its national market share to 20.1%, with notable gains in some states. International operations are showing growth, and the company has expanded its clinical network with new appointments. Operational and cost efficiency initiatives are in progress, with greater benefits expected in FY27.

FY26 Underlying NPAT expected to be $17M to $18M

Monash IVF expects operational and cost efficiency initiatives to contribute more meaningfully in FY27.